LOX-1在动脉粥样硬化中的细胞生物学效应及药物治疗新进展  

Progress in cell biological effects of LOX-1 in atherosclerosis and LOX-1 targeted medication

作　　者：郑旭 张丽霞 邓姣[2] 董海龙[2] ZHENG Xu1, ZttANG Li-xia1 , DENG Jiao2, DONG Hal-long2(1. Cadet Brigade, 2. Department of Anesthesiology, Xijing Hospital, Fourth Military Medical University, Xi＇an 710032, Shaanxi, Chin)

机构地区：[1]第四军医大学学员旅,陕西西安710032 [2]第四军医大学西京医院麻醉科,陕西西安710032

出　　处：《心脏杂志》2018年第3期348-354,共7页Chinese Heart Journal

摘　　要：动脉粥样硬化(AS)是一种血管慢性炎症性病变,低密度脂蛋白、氧化型低密度脂蛋白和其他修饰型的脂蛋白在血管内膜下的滞留和聚积被认为是AS的起始因素。凝集素样氧化型低密度脂蛋白受体(LOX)-1在AS的发生、发展中起重要作用,介导了多种信号对血管内皮细胞的刺激,是AS斑块形成的起始因素之一。近年来,不断有新的证据发现LOX-1与细胞外不同配体的相互作用及细胞内效应,并发现多种药物通过抑制LOX-1产生抗AS的作用。本文将着重阐述近年来LOX-1在AS发生、发展中的细胞生物学效应与相关药物治疗新进展。Atherosclerosis is a chronic inflammatory pathologic change of blood vessels. The retention and accumulation of low density lipoprotein, oxidized low-density lipoprotein, and other modified forms of modified lipoproteins in the intima of the vessels is considered to be one of the initiating steps for atherosclerosis. Lectin-like oxidized low-density lipoprotein receptor 1 （LOX-1） has been proven to be significantly important in the development and progression of atherosclerosis. Accumulating evidence has emerged to support the diversity of extraeellular legends for LOX-1 to induce intracellular effects. Current literature has revealed several drugs that could inhibit the progression of atherosclerosis through blocking or reducing LOX-1. The current review focuses on recent progress into the cell biological effects of LOX-1 in atherosclerosis and LOX-1 targeted medication.

关 键 词：氧化型低密度脂蛋白 动脉粥样硬化 凝集素样氧化型低密度脂蛋白受体-1 配体 治疗药物 

分 类 号：R543.5[医药卫生—心血管疾病]